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Abstract
Cells of the innate and the adaptive immune system have been identified as the key
players  in  inflammatory  bowel  disease  (IBD)  pathogenesis,  and  the  cytokines  are
central components of the inflammatory pathways that take place in the gut mucosa
during the  active  and chronic  phases  of  IBD.  The effector  cell  response is  largely
determined by the type of cytokines that predominate in the intestinal mucosa. Here
we describe the main cytokine players in intestinal inflammation during IBD—related
to innate immune responses (tumor necrosis factor α—TNFα), TNF-like cytokine 1A,
IL-8), and related to adaptive immune responses—Th1 (IL-1β, IL-18, IFNγ, IL-12), Th2
(IL-4,  IL-5,  IL-13,  IL-11,  IL-33),  Th17  (IL-17A,  IL-17F,  IL-21,  IL-22,  IL-25,  IL-27),
cytokines  required  for  Th17  development  (IL-6,  TGFβ,  IL-23),  anti-inflammatory
cytokine IL-10 and Tregs along with IL-2. Recently described innate lymphoid cells
(ILCs) could also be potential sources of IFN-γ, TNF, IL-5, IL-13, IL-17, and IL-22. The
effects of cytokines in the gut are described in conjunction with the clinical implication
and available biologic therapy. The data in the literature and our own results make us
believe that in order to achieve immune homeostasis in the gut, pro-inflammatory and
anti-inflammatory responses that define the mucosal cell immunophenotype should
achieve balance.
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1. Introduction
Both ulcerative colitis (UC) and Crohn’s disease (CD), usually referred to as inflammatory
bowel disease (IBD), are examples of complex disorders, which include inflammatory and
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autoimmune features with prominent intestinal immune dysregulation. Cells of the innate
and the adaptive immune system have been identified as the key players of IBD. Cytokines
are central components of the inflammatory pathways that take place during the active and
chronic phases of IBD. However, a clear picture of these processes is still missing. Since the
inflammation is located in the intestinal mucosa, the latter is the main source of biomarkers
in  IBD allowing  various  immunological  pathways  to  be  explored  in  the  gut.  Thus,  the
determination  of  cytokine  expression  profile  could  help  to  elucidate  the  local  immune
responses  during  intestinal  inflammation.  Expression  of  IBD-related  proteins  such  as
cytokines, chemokines, adhesion molecules,  and their corresponding cellular and soluble
receptors has revealed their significant role in the pro- and anti-inflammatory processes in
the inflamed gut mucosa. Indeed, the implication of some cytokines in the immunopatho-
genesis of IBD is investigated intensively and proved in experimental models of intestinal
inflammation. Lack of enough investigation in humans, however, predetermines the need for
further studies since it is proved that the common clinical phenotype of colitis may result
from largely diverse genetic or immunological backgrounds.
2. Intestinal inflammation and cytokines
Since the pathogenesis of IBD is related to both dysregulated innate and adaptive immune
pathways, which contribute to the aberrant intestinal inflammatory response in genetically
susceptible individuals, the main focus of research attempts is directed to the initiation,
perpetuation, and cessation of gut inflammation associated with IBD [1].
Cytokines are abundantly produced by the cells of the gut-associated immune system
maintaining lymphocyte homeostasis under both steady-state and inflammatory conditions.
These small, cell-signaling protein molecules act in a paracrine, autocrine, or endocrine
manner, coordinate the communication between immune and non-immune cells of the
intestinal compartment, and modify acute and chronic inflammatory responses at both local
and systemic levels [2]. Moreover, elevation of pro-inflammatory cytokines is considered to be
associated with the severity of gut inflammation [3]. Therefore, it is no surprise that cytokines
have been a major therapeutic management of IBD [4].
It is believed that dysregulated immune mechanisms are related to T cells in the gut in IBD
pathogenesis. Unregulated T lymphocytes activities can lead to autoimmunity, especially
during inflammation when they can cause excessive tissue damage [5]. The ability of CD4+ T
helper (Th) cells to alter the magnitude and outcome of the intestinal tissue-damaging
inflammatory responses is mostly dependent on the production of distinct profiles of cyto-
kines. Traditionally, the lesions in CD patients have been associated with a predominant
activation of Th1 cells and production of large quantities of IFNγ under the stimulus of IL-12
through STAT4 signaling. By contrast, the lesions in UC patients were believed to be driven
by Th2 cytokines, such as IL-4 and IL-13, through STAT6 activation. In the mouse model of
IBD, CD3+ (T cell) depletion results in dramatic reduction of the gross pathology, neutrophil
influx, and expression of pro-inflammatory cytokines and chemokines [6]. The cytokine
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expression pattern that strictly follows the polarization model of Th1 versus Th2, however,
does not appear to be fully applicable in IBD. Nearly 20 years ago, Mosmann and Coffman
concluded their paradigm with the prediction: “… further divisions of helper T cells may have
to be recognized before a complete picture of helper T cell function can be obtained” [7, 8].
Indeed, several recent studies had led to the identification of more complex networks of
cytokine interaction in IBD tissue, thus shedding light on the role of a distinct subset of T cells
in the pathogenesis of IBD—Th17 cells. On the other hand, another T cell subpopulation,
namely T regulatory cells (Tregs), is implicated in gut homeostasis and tolerance induction,
and it is believed that Th17 and Tregs are in a mutually polarizing relationship [9]. An overview
of the main cells and cytokines involved in intestinal inflammation is presented in Figure 1.
Figure 1. T-helper cells and cytokines interactions in normal and inflamed mucosa of IBD patients. The fate of naïve T
cell depends on the interactions with the antigen-presenting cells (i.e. dendritic cells, macrophages) and the secreted
cytokines. In normal mucosa, the abundant TGFβ1 directs naïve Th0 cells to Treg differentiation which secrete IL-10
and TGFβ1. “Danger” signals through TLR activation (on antigen-presenting cells), followed by secretion of IL-6,
IL-23, IL-1, etc., with the simultaneous presence of TGFβ1, all favor the development of Th17 cells. The latter secrete
many cytokines, for example, IL-21 acts as an autocrine positive regulator but IL-25 and IL-27 inhibit Th17 cells in au-
tocrine manner. Th17 cells could also secrete IL-17 cytokines, TNFα, and in special circumstances—IFNγ; thus, Th17
cells play an intermediate role between innate and adaptive immune response, especially during inflammation in the
intestinal mucosa. The balance between Th17 cells and Tregs is desired to maintain the immune homeostasis in the gut.
However, Tregs and Th17 cells can convert into each other demonstrating same plasticity, depending on the cytokine
milieu. Nevertheless, there are other players in the inflamed mucosa such as Th1, Th2, and Th22 cells. Legend: black
arrow—cell differentiation; green arrow—secretion; pink arrow—possible secretion; red arrow—inhibition; TCR—T
cell receptor; TLR—Toll-like receptor; MHCII—major histocompatibility complex—Class II; TL1A—TNFα-like 1 A.
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Thus, the effector response is largely determined by the combination of cytokines that
predominate in the intestinal mucosa, and it defines the mucosal T cell immunophenotype in
each case [2].
2.1. Innate immune response and related cytokines
Dendritic cells (DCs), macrophages, epithelial cells, and myofibroblasts are able to recog-
nize pathogen-associated molecular patterns (PAMPs) through their pattern-recognition
receptors including Toll-like and NOD-like receptors. This recognition results in nuclear
factor (NF)-kB activation with gene transcription and production of pro-inflammatory cy-
tokines, such as IL-1 and TNFα, ensuring an effective innate response against microbial
antigens. That also triggers antigen presentation, maturation, and up-regulation of co-
stimulatory molecules which lead to efficient adaptive immunity involving T cell activa-
tion [10]. There is evidence for down-regulated protein level of TLR-3 in IBD, whereas
TLR-2 and TLR-4 are up-regulated in intestinal mucosa of active IBD [11]. A specific mu-
tation in NOD2 gene induces loss of NF-kB function during TLR-2 activation with a sub-
sequent increased risk of infection with commensal bacteria and increased susceptibility
to the ileal form of CD [12]. Recent studies suggest that increased mucosal permeability in
the intestinal mucosa during IBD flare allows infiltration of a large number of granulo-
cytes into the colonic mucosa. These leukocytes are activated, have a prolonged survival
time, and release various pro-inflammatory cytokines (e.g. IL-1β, IL-6, TNFα, IL-18),
which exacerbate and maintain the inflammation in the gut [13].
2.1.1. TNFα
TNFα links the innate and the adaptive immune responses and has crucial importance in the
pathogenesis of IBD by inducing the differentiation of stromal cells into myofibroblasts and
promoting their production of matrix metalloproteinases. The latter induce enterocyte
apoptosis and digestion of gut basement membrane [10]. TNFα also exerts its pro-inflamma-
tory effect through cytokines such as INFγ, IL-1β, and IL-6 [12].
TNFα is a well-established inflammatory mediator in CD whereas contradictory reports exist
in UC [12]. There is a lack of studies on the mucosal expression of TNFα and the prediction of
the clinical course, and only a few reports announced the predictive value of mucosal TNFα
concentrations and the response to therapy in IBD patients. In fact, increased levels of TNFα
and IL-15 have been previously reported in intestinal biopsies from IBD patients in remission
without biopsy alterations [14]. Interestingly, the presence of TNFα in non-affected areas of
IBD mucosa may not be sufficient to trigger mechanisms of mucosal damage. In preliminary
reports, normalizing of mucosal TNFα seemed to predict a longstanding remission after
stopping of anti-TNFα therapy in UC [12].
Certain TNFα polymorphisms (i.e. TNFα-308 A allele) are associated with increased serum
levels of TNFα and therefore with higher susceptibility of IBD [15].
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2.1.2. TNF-like cytokine 1A
TNF-like cytokine 1A (TL1A) is a novel member of TNF superfamily of proteins, produced by
endothelial cells, macrophages, lamina propria T cells and plasma cells, monocytes, and
monocyte-derived DCs [16]. Association with its functional receptor provides co-stimulatory
signals for activation of T lymphocytes, leading to cell proliferation, cytokine secretion, and
amplification of pro-inflammatory pathways, as well as induction of apoptosis in target cells
[2]. Several studies have clearly demonstrated that TL1A and its receptor are up-regulated at
mucosal protein and mRNA levels in IBD patients. TL1A is localized in the lamina propria and
shows preferential expression on plasma cells and mucosal DCs. Of great importance is the
fact that TL1A was shown to increase IL-13 secretion by natural killer T (NKT) cells, which are
considered to be central to the mucosal injury that takes place in UC pathogenesis. Further-
more, TL1A induces IFNγ secretion in synergy with stimulation via TCR or IL-12/IL-18 [2].
TL1A expression is induced by TNFα and IL-1α as well and since the latter are abundantly
expressed in the inflamed mucosa of UC patients, they may provide a strong stimulus for
enhanced TL1A expression. On the other hand, several microorganisms were shown directly
to stimulate TL1A secretion by DCs via TLR-signaling (TLR-4), LPS-induced and NFkB-
dependent pathway [16]. Moreover, there is an inhibitory component of the TL1A receptor
which could augment pro-inflammatory pathways at the intestinal mucosa by rendering
activated lymphocytes resistant to apoptosis. Thus, increased expression of this inhibitory
TL1A receptor may offer a survival advantage to effector lymphocytes, preventing their
elimination and perpetuating tissue injury [2].
2.1.3. IL-8
IL-8, as a member of the CXC chemokines family, is not only a strong chemoattractant for
neutrophils, monocytes, etc. but also triggers the secretion of superoxide anions and lysosomal
enzymes in neutrophils, thus contributing to the tissue damage during inflammation. IL-8
mRNA expression in the inflamed mucosa is shown to be significantly higher than the level
in non-inflamed mucosa of IBD patients or in the normal mucosa of non-IBD patients [13].
2.2. Th1 profile-related cytokines
Th1 cells are an essential part of the adaptive immune response, mainly against intracellular
microorganisms and protozoa. The master transcription factors for Th1 definition are STAT4
and T-bet. Th1 cells in gut mucosa which are induced by increased levels of IL-12 and IL-18
are thought to cause intestinal inflammation in CD patients via production of high amounts
of IFNγ. The latter induces enterocyte apoptosis and triggers the release of TNFα by activated
mucosal macrophages. Th1 cells by themselves appear as an important source of TNFα [10].
2.2.1. IFNγ
IFNγ is a mediator of intestinal inflammation in CD, but contradictory reports exist for UC.
However, increased levels of IFNγ have been observed in the inflamed mucosa from UC
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patients too. IFNγ levels also correlated with the clinical activity but not with the endoscopic
score in UC, whereas no correlation to the clinical activity was observed in CD patients [12].
2.2.2. IL-12
The role of IL-12 in intestinal inflammation will be discussed later along with IL-23.
2.2.3. IL-1
IL-1 exists in two forms, IL-1α and IL-1β, encoded by different genes but exhibit almost
identical functions [16]. The major sources of IL-1 are activated myeloid cells and its production
can be induced by bacterial lipopolysaccharide, TNFα, IFNα, IFN-β, IFN-γ, as well as IL-1.
IL-1 was found to promote Th17 development in the presence of IL-6 and TGFβ, and also to
potentiate their actions in humans but not in mice. Moreover, it has been reported that IL-1
can increase their effect on Th17 definition. However, the mechanism through which IL-1
influences Th17 differentiation is not fully determined yet [17]. Some suggestions include that
IL-1β or IL-1α cooperates with IL-23 to enhance IL-17 production independent of TCR
stimulation. Additionally, IL-1 may suppress the inhibitory effect which IL-2 exerts on Th17
cell production through induction of IL-1R, IL-23R, and transcription factor RORγt [16].
IL-1β was shown to be increased in CD and UC patients, whereas the IL-1-receptor/IL-1β ratio
was negatively associated with the IBD activity. When comparing the IBD patients with
controls, a significant variation in genotype frequency of the IL-1β promoter polymorphism
was found. Higher levels of the pro-inflammatory cytokine IL-1β would be expected to increase
the likelihood of developing IBD since higher levels of such cytokines occur in this disease [15].
2.2.4. IL-18
IL-18 is another member of the IL-1 pro-inflammatory cytokine family. IL-18 is an epithelial-
derived cytokine that has been proposed to promote barrier function in the intestine, but its
effects on intestinal T cells are poorly understood. Although IL-18 is mainly responsible for
inducing IFNγ production and Th1 differentiation, this cytokine might be involved in Th17
cell definition as well. Antigen-presenting cells express IL-18R on their surface and its binding
with the cytokine is required for generation of Th17 cells through an IL-23-dependent mech-
anism. Moreover, IL-18 synergizes with IL-23 in the induction of Th17 cell [16] However, there
are more reliable proofs about the involvement of IL-18R in Th17 cell definition, but not for
IL-18 itself. Probably this action might be fulfilled through binding of an unknown alternative
ligand, distinct from IL-18, to the receptor [17]. In contrast, Maloy et al. [18] demonstrated that
during steady state, intestinal epithelial cells constitutively secrete IL-18, which acts directly
on IL-18R1-expressing CD4+ T cells to limit colonic Th17 cell differentiation. In addition, they
found that IL-18R1 signaling was critical for Tregs-mediated control of intestinal inflammation,
though IL-18R1 is not required for Tregs development [18]. Thus, since IL-18 may regulate
differentially homeostatic and inflammatory subsets of T cells, this finding has potential for
treatment of IBD and other chronic inflammatory disorders.
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IL-18 was found elevated in the inflamed colonic mucosa of UC and CD patients and poly-
morphisms in the IL-18R1-IL-18RAP locus are associated with IBD susceptibility [18]. More-
over, the local expression of IL-18 has been shown to be associated with the grade of
inflammation [19].
2.3. Th2 profile-related cytokines
Th2 cells, another important part of the adaptive immune system, are mainly involved in the
effector responses against extracellular parasites, including helminths, as well as in allergy
pathogenesis. They are defined by the transcription factors STAT6 and GATA3 [7]. The
importance of Th2 response in IBD is still under debate. In UC, the inflammatory response is
less skewed along specific pathways, even though there is enhanced production of IL-4, IL-5,
and IL-13, cytokines made by Th2 cells, unlike CD where Th1 activation has been mainly
employed in pathogenesis [20].
2.3.1. IL-13
IL-13 exerts the potential to increase intestinal permeability and induce both enterocyte
differentiation and apoptosis. IL-13 is released mainly by Th2 cells but another source of that
cytokine is NKT cells. NKT cells express surface CD161 but not invariant T cell receptor, which
is a well-established characteristic of this population. They produce IL-13 in response to
stimulation of antigen-presenting cells expressing surface CD1d. Most probably, these atypical
NKT cells are stimulated to produce IL-13 in the colonic mucosa by flora-derived microbial
products [2]. This was observed in patients with UC, but not in CD patients. Further studies
revealed that CD161-expressing NKT cells showed IL-13-dependent cytotoxic activity against
colon epithelial cells [2]. Moreover, IL-13 independently exerts harmful effects on epithelial
barrier function, such as derangement of tight junction integrity, decreased restitution velocity,
etc. [2]. Therefore, blockade of IL-13 downstream signaling may be an effective anti-inflam-
matory approach in UC which requires further investigations.
2.3.2. IL-11
IL-11 is a member of the IL-6 cytokine family and exerts pleiotropic effects on various cell types
as it acts synergistically with other cytokines such as IL-3 and IL-4, thus it has been implicated
in Th2-mediated sensitization and inflammation. IL-11 also prevents cell death and inhibits
inflammation at sites of tissue injury. IL-11 mediates anti-inflammatory effects by down-
regulation of LPS-induced NFkB activation, thus preventing transcription of inflammatory
genes [12]. This may be implemented in IBD therapy, but still needs additional verification.
2.3.3. IL-33
IL-33 is the latest identified member of the IL-1 family of cytokines. mRNA and protein
expression of IL-33 was detected in normal colonic cells both at the surface epithelium and in
crypts, as well as in inflamed bowel onto lamina propria mononuclear cells (CD11b+ mono-
cytes/macrophages and CD19+ B cells), endothelial cells, and subepithelial myofibroblasts.
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During active intestinal inflammation, IL-33 actively participates in the epithelial-immune cell
crosstalk that takes place in IBD mucosa. IL-33 expression is augmented under stimulation
with IL-1β and TNFα, two cytokines that are enriched at the inflamed mucosa and are of
pathogenic relevance in UC, as well as after TLR-3 and TGFβ signals [2].
Regarding mucosal expression, up-regulation of IL-33 appears to be specific for UC, as it was
not observed in CD colonic inflammation [2]. Moreover, IL-33-expressing myofibroblasts were
absent in fissuring areas in patients with colonic CD. Therefore, these observations may
provide information of distinctive pathway between the two forms of IBD [2].
IL-33 was shown also to induce particularly the expression of Th2 effector molecules IL-5 and
IL-13. Given the central role of IL-13 in UC, IL-33 may be involved in UC pathogenesis through
the induction of IL-13 secretion. It has been proposed that IL-33 may function as “alarmin” for
the gut-associated immune system activating toward intestinal inflammation or perpetuating
the ongoing one [2].
2.4. Prerequisite cytokines for Th17 development
To emphasize the importance of Th17 in intestinal inflammation, here we start with the
description of the prerequisite cytokines for the development of Th17 cells from naïve T cells.
2.4.1. TGFβ1
Transforming growth factor β (TGFβ) is a potent cytokine with multi-faceted regulatory and
inhibitory activities and has two forms—TGFβ1 and TGFβ2. TGFβ1 is a pleiotropic cytokine
best known for its potential to induce peripheral tolerance in the absence of IL-6 [12]. One of
the mechanisms by which TGFβ1 is able to maintain tolerance is to support the survival of
naturally occurring FoxP3+ Tregs (nTregs) in thymus. In addition, along with IL-2 and retinoic
acid, TGFβ1 promotes the differentiation of induced Tregs (iTregs). Another mechanism of
TGFβ-induced tolerance is to suppress the innate immune cells such as DCs and NK cells [5].
TGFβ1 also regulates the development of resident macrophages in the normal intestine, which
possess some unusual features such as constitutive production of IL-10 and TNFα, refractory
to TLR stimulation, high expression of MHCII and CXCR1, and avid phagocytic activity. Thus,
this is another mechanism through which TGFβ1 favours local homeostasis [21].
TGFβ1 plays an important role under inflammatory conditions. In the presence of IL-6,
TGFβ1 drives the differentiation of Th17 cells which promotes further inflammation and
augmentation of ongoing autoimmune conditions. In addition, TGFβ1 in combination with
IL-4 promotes the differentiation of IL-9-producing and IL-10-producing T cells, which
surprisingly lack suppressive function and also promote tissue inflammation [12]. Increased
protein levels of TGFβ1 are found in the mucosa of both CD and UC patients, whose levels
correlated with the severity of disease in CD but not in UC patients [5, 12]. We also found
significantly higher gene and protein levels of TGFß1 in the inflamed mucosa of CD patients
alone [22]. This is not surprising since the tissue remodeling properties of TGFβ1 are well-
established. Interestingly, TGFβ1 orchestrates the differentiation of both Tregs and Th17 cells
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in a concentration-dependent manner—low doses induce Th17 cell differentiation while
higher doses inhibit Th17 cell development and promote Tregs [5, 11].
2.4.2. IL-6
IL-6 is a pleiotropic cytokine with regulatory effects on inflammation development. In addition
to its stimulatory effects (i.e. induction of acute phase proteins), IL-6 also has inhibitory
functions (i.e. cessation of the antiviral antibody response after certain immunizations). Recent
studies have demonstrated that IL-6 has a crucial role in the regulation of the balance between
Th17 cells and Tregs [23]. IL-6 activates a receptor complex consisting of IL-6R and the signal
transducing subunit gp130 which activates downstream STAT1 and STAT3. STAT3 regulates
IL-6-induced expression of RORγt and RORα, the crucial transcription factors for Th17 cells.
In contrast to STAT3 activation, STAT1 inhibits the development of Th17 cells. Although IL-6
activates both STAT1 and STAT3, it has been demonstrated that in Th17 cell activation, they
play two different roles—STAT3 maintains while STAT1 suppresses it [23]. Furthermore, STAT
family members activated by various cytokines provide both positive and negative regulation
for Th17 development (i.e. IL-27 inhibits Th17 differentiation through STAT1) [23]. TGFβ1 can
induce gene activation of both FoxP3 and RORγt, but FoxP3 is able to associate with RORγt,
thus inhibiting its transcriptional activation. Nevertheless, in the presence of IL-6 this inhibi-
tion is abrogated, so IL-6 could act as a potent promoter of Th17 instead of Tregs differentiation.
All facts taken together, IL-6 appears as the main partner of TGFβ in priming naïve T cells to
IL-17 production, playing a pivotal role in Th17 polarization and initiation of inflammatory
immune response. Currently, it is also accepted that IL-6 is able to induce expression of IL-23R
in T cells, making them responsive to IL-23 which sustains the Th17 phenotype [17].
Increased levels of IL-6 and its soluble receptor are up-regulated in active CD patients, and
mucosal IL-6 levels were correlated with the degree of clinical activity in CD and UC [12]. In
consent with these findings, in a group of 37 IBD patients, we also found both mRNA tran-
scripts of TGFβ1 and IL-6 up-regulated in patients’ mucosa compared to the mucosa of non-
IBD persons, along with increased IL-17 mRNA in inflamed tissue [22, 24].
Several polymorphisms regarding the IL-6 gene are described to be also associated with
susceptibility to IBD development, such as IL-6 174 [15].
Although anti-IL-6 antibodies therapy has become a novel therapeutic strategy for some
inflammatory and autoimmune disease, including CD, IL-6 inhibitory treatment acts primarily
on initial CD4+ T cells response including Th17 differentiation, rather than on the effector
phase [23]. However, it still remains controversial whether this antibody can inhibit Th17
differentiation in a manner that is clinically meaningful.
2.4.3. IL-23
IL-12 and IL-23 share the common p40 subunit, but whereas IL-12 drives the classical Th1
response characterized by IFNγ production, IL-23 maintains an IL-17-secreting T cell popu-
lation. Th1 responses may develop normally in the absence of IL-23, but in IBD patients, their
manifestations require the presence of IL-23. The systemic inflammatory response and the
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elevated concentrations of pro-inflammatory cytokines in the serum are driven by IL-12 while
the local intestinal inflammation and production of IL-17 in the intestinal mucosa are controlled
by IL-23 [11, 12, 25].
IL-23 is crucial in orchestrating the crosstalk between innate and adaptive immunity with a
key role in driving early responses to microbes. In a recent study, Kamada et al. showed that
IL-23 is secreted preferentially by a subset of sentinel mucosal cells expressing both macro-
phage (i.e. CD14, CD33, CD68) and DC markers (i.e. CD205, CD209) [26]. These cells are present
in a large number in CD-involved tissue and produce IL-12 and IL-23 in response to environ-
mental danger signals [8, 26]. The presence of pathogens or pathogen-related products (such
as lipopolysaccharide) can strongly influence the production of IL-12 and/or IL-23 depending
on the microbial agent. This happens within a few hours after exposure and these early events
in pathogen encounter are likely to shape subsequent responses toward IL-12 or IL-23
expression [8]. It was shown that some of the pathogenic functions of IL-23 in the gut are
mediated by atypical T cell populations, such as γδT cells, invariant NK cells, and innate
lymphoid cells, inducing them to secrete Th17-related cytokines and contributing to intestinal
inflammation [10]. IL-23 might be also closely associated with the neutrophil influx [12].
The precise function of IL-23 in Th17 regulation is still not entirely clear, although there are a
lot of speculations. IL-23 failed to induce the differentiation of naïve T cells into Th17 cells due
to lack of IL-23R on naïve T cells [16]. It was subsequently demonstrated that IL-23R is not
expressed on naïve T cells. Instead, IL-23 acts as a survival signal for Th17 cells by the mech-
anism probably similar to TNFα [23, 27].
The synthesis of the common p40 subunit for both IL-12 and IL-23, and the functional heter-
odimeric IL-23 is enhanced in the gut of CD patients [11]. Along with other authors’ findings,
we detected up-regulated mRNA levels of IL-23 in inflamed mucosa, as well as significantly
increased serum level of IL-23 among IBD patients in comparison with non-IBD persons [24],
and we suggest that anti-IL-23 therapy could be beneficial for IBD patients.
Identification of multiple single nucleotide polymorphisms (SNPs) in the IL-23 receptor gene
that has been associated with both UC and CD suggested that the IL-23 axis might play a central
role in chronic inflammation. IL-23R SNPs that influence IBD susceptibility have provided a
new picture of the way the local immune response can promote intestinal tissue damage [11].
Small differences in cytokine levels as a result of gene polymorphisms may have an important
effect on the inflammatory response and thus, influence the pathophysiology of IBD [15].
Interestingly, one of these polymorphisms, Arg381Gln, confers protection against developing
CD [20]. Nonetheless, the mechanism through which these SNPs confer either risk or protec-
tion from IBD remains unknown [15].
2.5. Th17 cells and produced cytokines
The discovery of an IL-23-dependent T cell population that produces IL-17 but not IFNγ or
IL-4 suggested there is an additional Th cell subset. Th17 cells have derived their name from
their ability to produce IL-17, also termed IL-17A. Th17 cells also produce other cytokines
including IL-17F, IL-21, IL-22, TNFα, and IL-6 [17, 23]. However, analysis at the single cell level
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has revealed that not all Th17 cells secrete the whole spectrum of cytokines, probably reflecting
the heterogeneity of this cell’s subset [25]. The IL-17 cytokine family also includes IL-17B,
IL-17C, IL-17D (IL-27), IL-17E (IL-25), and IL-17A/F (Figure 1). The cytokines IL-27 and IL-25
have lowest protein homology to IL-17A. They are not produced by Th17 cells but act as
negative regulators on the Th17 subset development. IL-27 is structurally related to IL-6 and
is able to attenuate chronic inflammation by promoting IL-10 production [17]. In line with this,
IL-27 and IFNγ are responsible for the inhibition of Th17 development in a STAT1-dependent
manner [23], as described above. Another negative regulator of Th17 cells is IL-25, identified
as a genetic homologue of IL-17, produced by Th2 and mast cells. IL-25 is involved in the
expression of the Th2 cytokines IL-5 and IL-13, thus, favors Th2 responses. IL-25 deficiency is
involved in pathologic inflammation, associated with increased expression of IL-17 and IL-23
[17].
CCR6, presented not only on Th17 cells, but also on Tregs, B cells, neutrophils and immature
DC, plays a critical role in the migration of these cells to the sites of inflammation. TGFβ1 was
shown to be the main factor for induction of CCR6 mRNA expression in Th17 cells and DCs
[19]. IL-17-producing Th memory cells selectively express both CCR6 and CCR4, unlike Th
cells producing IFNγ or both IFNγ and IL-17 which express CCR6 and CXCR3 [16]. Indeed,
CCR4 is important for homing to the gut, where most RORγt+IL-17+ T cells are found [16].
The relationship among Th1, Th2, and Th17 cells is complex and still not clear. Th1- and Th2-
related cytokines inhibit Th17 cell differentiation while IL-17 is not able to suppress Th1 or Th2
cells, or does it weakly. The suppression of IFNγ and IL-4 or their absence represents a way
by which TGFβ1 could promote Th17 cell development. TGFβ1-driven Th17 cell differentiation
can also occur in the absence of IFNγ and IL-4 [11]. In parallel with these findings, it was
reported that IL-17-producing cells could be generated independent of the specific cytokines
and transcription factors required for Th1 and Th2 differentiation [17]. Moreover, Th17 cells
could develop from naïve T cells only in the combined presence of IL-6 and TGFβ1 [12, 20].
Thus, TGFβ induction of Th17 cells and also of Tregs, which are usually contradictory acting,
is dependent on the presence of IL-6. This explains the apparent discrepancy of TGFβ1
involvement in both anti- and pro-inflammatory events in the intestine mucosa [17].
2.5.1. IL-17
IL-17 is an effector cytokine in gut immunity, which may have either pro-inflammatory or
tissue-protective effects in the mucosa depending on the experimental or clinical model used.
On one hand, IL-17 contributes to the mucosal barrier function by several mechanisms which,
upon activation, result in a mucosal immune response toward pathogens [6]. IL-17 also
promotes tight junction formation and increases trans-epithelial resistance in polarized
intestinal epithelial cells by stimulating the production of antimicrobial peptides such as
lipocalin-2, β-defensins, and calprotectin. This suggests that the latter are involved in the
maintenance of immunological homeostasis and/or in the control of specific inflammatory
pathways [19]. Thus, the Th-17-related cytokines mediate protective effects in host gut against
various bacteria and fungi, particularly at mucosal surfaces [10, 11]. Interestingly, pathogens
that have evolved to take advantage of various aspects of the mucosal response gain an edge
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over the resident commensal bacteria and colonize the gut with priority. Despite that Th17
responses appear to be detrimental by promoting pathogen colonization of the mucosa, in the
end, they result in decrease in bacterial dissemination from the mucosa that protects the host
by inducing slight inflammation [6]. In line with this, it was shown that Th17 cells are consti-
tutively present in the human and mouse intestinal mucosa and that Th phenotype is driven
by the commensal bacteria in the gut. Additionally, stimulation of DCs with TLR ligands (e.g.
fungal Dectin-1) induces synthesis of IL-6, TNFα, and IL-23 that promotes the differentiation
of Th17 cells [11]. From this point of view, blocking Th-17 cytokines could have more delete-
rious than beneficial effects for the host [25].
On the other hand, IL-17 might mediate tissue inflammation by triggering several inflamma-
tory pathways and by inducing various pro-inflammatory cytokines (e.g. IL-1, IL-6, TNFα, G-
CSF, GM-CSF), chemokines (e.g. IL-18, CXCL-1, CXCL8, MIP-1), and enzymes (COX-2, matrix
metalloproteinases). Both IL-17 and IL-22 stimulate granulopoiesis by inducing expression of
the granulocyte colony stimulating factor (G-CSF) and IL-17A which rapidly recruits neutro-
phils to the inflammatory site. This mechanism has important evolutionary significance [25].
The neutrophil response gains time for the induction of the following antimicrobial Th1-
IFNγ response which takes several days to develop. Once the appropriate immune effector
functions occur, the IL-12/IFNγ axis becomes the dominant pathway in host defence. This is
important for initial control of the infection, but if the IL-23/IL-17 immune pathway becomes
dysregulated, there is a danger of autoimmune pathology development, such as IBD. These
observations, including the fact that T-bet is expressed at lower level in Th17 cells, led McKen-
zie et al. to favour the hypothesis of a common lineage precursor of Th1 and Th17 cells [8].
Furthermore, the tissue localization and timing of IL-12 versus IL-23 responses explain the idea
that IL-12/IFNγ axis is involved in systemic inflammatory conditions (such as lupus), whereas
the IL-23/IL-17 axis appears to regulate tissue-specific disorders (such as IBD) [8].
Another layer of complexity to the mucosal existence of Th17 cells is other cell types, which
can secrete IL-17-related cytokines: γδT cells (secreting IL-17 in response to IL-23), NK, NKT
cells (able to produce IL-17 and IL-22), and DCs (can secrete IL-22 in response to bacterial
infection). Paneth cells, which are common in the ileum, also secrete IL-17A [6, 19]. As all these
cells express the IL-23 receptor, the secretion of IL-23 by DCs comprises a trigger which
potentiates early T cell activation and adaptive immunity development [6]. Thus, it appears
that early activation of both adaptive and atypical innate-like T cells can lead to the expression
of IL-17 and IL-22. However, dysregulated production of IL-17, IL-22, and TNFα in local tissue
can result in chronic immune-mediated tissue destruction [8].
Studies in murine models of IBD strongly suggest that Th17 cells and their related cytokines
contribute to tissue-damaging immune responses in the gut [25]. Up-regulation of Th17-related
cytokines, however, does not represent a specific hallmark of IBD in humans, as increased
levels of IL-17A and other Th17-related-markers have been seen in patients with rheumatoid
arthritis, multiple sclerosis, psoriasis, etc. [11]. Immunohistochemistry studies have shown that
in active UC, the IL-17-expressing cells were located mainly within the lamina propria, while
in active CD, these cells were scattered throughout the submucosa and muscularis propria of
the gut. Corresponding with this, it was shown that RNA transcripts for IL-17A and IL-17F
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were up-regulated in the inflamed mucosa of UC and CD patients [3, 11, 22, 28]. Both IL-17
and IL-23 are correlated to the severity of UC [12]. More recently, Annunziato et al. demon-
strated that the number of IL-17-producing T cells is higher in CD than in normal gut mucosa,
and some of these cells also produce IFNγ [29].
Th17 cells have shown possession of functional plasticity. Some of the IL-17A-producing cells
simultaneously express IFNγ (Figure 1). Majority of IL-17/ IFNγ-producing cells express
CD161, a well-known marker of NKT cells, also identified recently on IL-17-producing
memory T cells [11]. Th17 cells can be converted into Th1 cells if they receive appropriate
stimuli, such as IL-12 which enhances the expression of Th1-related markers (i.e. T-bet and
IFNγ) and down-regulates RORγt and IL-17. Additionally, recent studies have shown that
treatment of intestinal lymphocytes with IL-23 can facilitate the production of either IL-17A
or IFNγ in UC or CD, respectively [11].
This is in consent with the demonstration that some of the pathogenic effects of IL-23 in the
gut are linked to the ability of this cytokine to turn on IFNγ production. Switching from IL-17A
to IFNγ production occurs if Th17 cells are activated by a lack of TGFβ1 [25]. Th17 cells and
their possible conversion to Treg direction is going to be described later.
This very complex and non-equivocal relationship of both pro-inflammatory and tissue-
protective effects of IL-17 in the gut may explain the unsuccessful anti-IL-17 therapy in CD
patients [10].
2.5.2. IL-21
IL-21, an IL-2-related cytokine produced by Th17 cells in response to IL-6, increases the
expansion of this cell subtype by a positive autoregulatory feedback loop. IL-21, which is up-
regulated in inflamed IBD mucosa, induces Th1 and Th17 immune responses in the mucosa
[10], but a mixture of both Th1 and Th17 cytokines is needed to promote full pathology in the
gut. In this context, a promising inducer could be IL-21, whose activity seems to be necessary
for expanding both Th1 and Th17 cell responses in the intestine. [25]. As we have already
noticed, IL-21 is overproduced in the gut mucosa of IBD patients, but the vast majority of IL-21-
producing CD4+ T cells co-express IFNγ but not IL-17A. This fact suggests that Th1 but not
Th17 cells are the major sources of IL-21 in the human gut [11]. There is evidence that IL-21
also enhances the expression of Th1-related transcriptional factors and IFNγ production in
NK cells [11].
IL-21, like IL-17, stimulates gut fibroblasts to produce tissue-degrading matrix-metalloprotei-
nases and enhances the secretion of chemoattractants (i.e. MIP-3α) by epithelial cells [10, 11].
IL-21, like IL-6, could also initiate Th17 differentiation together with TGFβ1 [23], even in the
absence of IL-6 [16, 17]. IL-21 enhances the expression of IL-23R in Th17 cells, through a process
that is dependent on STAT3 and RORγt, making these cells responsive to IL-23. IL-21 as well
exerts additional biological functions that could contribute to its pro-inflammatory effect in
the gut like inhibition of the peripheral differentiation of Tregs and making CD4+ T cells
resistant to Treg-mediated immune suppression [11].
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2.5.3. IL-22
IL-22 is a member of the IL-10 cytokine family and a Th17-related cytokine but it appears to
be differentially regulated. IL-22 provides signals through a heterodimer comprising IL-22R
and IL-10Rβ. The IL-22 receptor is highly expressed in tissues such as epithelial cells of the
gastrointestinal tract. Via STAT3 signaling pathway, the activation of proliferative and/or anti-
apoptotic programs starts, and this allows maintenance of epithelial barriers of the gut [5].
Most of the Th17 cytokines are highly dependent on the transcription factor RORγt for their
expression, unlike IL-22 whose expression is dependent on the transcription factor aryl
hydrocarbon receptor [5]. Th22 cells are another Th subpopulation characterized by the
expression of this transcription factor and secretion of mainly IL-22 [5].
IL-22 has a dual functional nature in modulating the responses during tissue remodeling. IL-22
promotes induction of acute inflammatory proteins, mucins, and antimicrobial peptides (i.e.
β-defensins), which are important for tissue integrity during inflammation. This mechanism
ensures proper organ function and escape of potentially harmful effects by restricting the
passage of luminal commensal flora and food antigens to the lamina propria [5, 25, 30]. It is
important to point out that this process depends on the inflammatory context (the overall
cytokine milieu and the tissues involved). Thus, IL-22 is important for control of pathogenic
bacteria that need to translocate through host epithelial barriers to disseminate, especially in
the gastrointestinal tract [5]. IL-22 also enhances intestinal barrier integrity by stimulating
epithelial cell growth, goblet cell restitution, and mucus production, thus contributing to the
healing of damaged tissue.
On the other hand, IL-22 can cause further inflammation by stimulating colonic fibroblasts to
secrete inflammatory cytokines (e.g. TNFα, IL-8, IL-11, and leukaemia inhibitory factor), IL-6,
chemokines, and matrix metalloproteinases [11]. It is not surprising that IL-22 is highly
expressed during chronic inflammation [5] in mucosal samples of patients with active CD,
because of the known dysbacteriosis and expected pathological microbial agents, and to a
lesser degree in patients with UC, where autoimmune phenomena are more common.
IL-22 is also expressed by innate immune cells such as CD11c+ and NK cells located in the
colon. The latter cells do not secrete IFNγ and are not highly cytotoxic [30]. IL-23, a traditional
activator of NK cells, induces IL-22 expression in NK cells. Unlike TGFβ and IL-10 that directly
modulate the immune response, IL-22 does not have direct effects on immune cells since these
cells lack the expression of IL-22R [30]. This way, TGFβ1 and IL-10 are involved in maintaining
immune homeostasis under steady-state conditions instead.
IL-22 is an ideal therapeutic candidate since it specifically modulates tissue remodeling and
does not have direct effects on the immune response. Treatment with recombinant cytokine or
gene therapy delivery of IL-22 may alleviate tissue destruction during inflammation owing to
its selective modulation of tissue responses [5].
2.6. Role of FoxP3+ Tregs and related cytokines in gut inflammation
The main function of Tregs is to modulate the adaptive immune responses, and forkhead/
winged helix transcription factor forkhead box P3 (FoxP3) is the master transcription factor
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for Tregs [23]. Two main subpopulations of Tregs have been best described: naïve (nTregs) and
inducible Tregs (iTregs). The latter is believed to be derived by peripheral transformation of
naïve T cells stimulated by IL-19, vitamin D3, antigens, and TGFβ1. So far, Treg function in
IBD is not completely characterized [12].
Tregs are crucially involved in the maintenance of gut mucosal homeostasis by suppressing
abnormal immune responses against the commensal flora or dietary antigens. They exert their
function by producing the anti-inflammatory cytokines IL-10 and TGFβ, thus preventing both
the activation and the effector function of T cells. Additionally, the regulatory activities of the
immune response through mediators such as IL-10 and TGFβ still need to be profiled,
especially those that might take place in the unaffected areas of IBD patients [14]. A certain
number of Th17 and CD4+CD25+FoxP3+ Tregs cell is presented in the intestine even in the
healthy state, partly due to the presence of enteric bacteria which favor the production of both
Th17 and Tregs. DCs in the intestine or mesenteric lymph nodes also actively promote the
production of both cell types. However, there are points of divergence, for example, the retinoic
acid produced by DCs in the intestine induces only Tregs. In spite of the essential function of
IL-2 as a growth factor of effector T cells, including Tregs, IL-2 has an inhibitory effect on Th17
cell production. Furthermore, IL-2 deficiency leads to systemic autoimmune disease, partly
because of its involvement in the differentiation and survival of Tregs [16]. Recent studies have
revealed that IL-2 deficiency promotes differentiation of Th17 cell subset in a STAT5-dependent
mechanism. At present, the recognized precise mechanism is exerted by suppression of IL-17
expression by directly binding to the IL-17 gene promoter of STAT5 [16].
The importance of Tregs in maintaining immune homeostasis was once again emphasized with
the X-linked IPEX syndrome (immune dysregulation, polyendocrinopathy, enteropathy),
caused by mutation of FoxP3. IPEX patients quite often complain of gastrointestinal symptoms,
suggesting that Tregs dysfunction may be involved in human IBD too [31].
A significant increase in production of Tregs in active-phase IBD mucosal lesions, as well as
decreased numbers of Tregs in peripheral blood of IBD patients was described [9]. However,
in active IBD a reduced number of peripheral Tregs have been reported to be reverted by anti-
TNF treatment [12]. Indeed, Tregs are increased in the intestinal mucosa of IBD patients in
comparison with the mucosa of healthy volunteers [22, 24, 27, 32]. Tregs isolated from inflamed
tissue display no obvious defect in their suppressive function, at least in vitro [9]. However,
Monteleone et al. found that Tregs obtained from the active-phase IBD mucosal lesions possess
an ability to suppress T cell activation [11, 25]. Since Th17 cells appear to be resistant to the
Tregs-mediated immunosuppression, it is likely that during chronic inflammatory process,
such as in IBD, Tregs may be dysfunctional and might augment rather than suppress Th17-
mediated immune responses [11]. At first, this phenomenon was explained as a feedback loop
associated with an increase in the Treg cell attracted by IL-2 which is produced locally at sites
of inflammation. On the other hand, however, up-regulated Th17 cells in response to increased
production of pro-inflammatory cytokines were postulated [27]. Th17 cells, but not Tregs, are
induced in the presence of pro-inflammatory cytokines, in addition to TGFβ1. Thus, Treg
dysfunction may not be intrinsic but rather due to extrinsic milieu of activated cells that are
resistant to suppression, and pro-inflammatory settings in the affected IBD mucosa [9, 33].
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Plasticity of Tregs and Th17 is further demonstrated by the possibility of conversion between
both subsets [27, 33]. Hu et al. have reported that Tregs express membrane-bound TGFβ and
in the presence of IL-6, they convert to Th17 cells [34]. This could be an important warning
regarding cell therapy with Tregs to treat chronic immune disease, including IBD, because the
“homeostatic” Tregs may convert to pathogenic Th17 cells during inflammation where IL-6 is
abundant [27]. Numerous studies have shown that in inflammatory cytokine environment,
Tregs can lose FoxP3 expression and acquire expression of other transcription factors that
define another lineage of CD4+ T cells as well as effector function. As we have already
mentioned, exposure of Tregs to IL-6 results in a partial conversion to Th17 cells. Interestingly,
although most IL-17-producing cells lost FoxP3 expression, some cells express both FoxP3 and
IL-17. It is unclear, however, whether the resultant cells are suppressive [9]. So, once again it
must be mentioned that the Th17/Tregs balance appears to play a very crucial role in IBD
development [27].
2.6.1. IL-10
IL-10 is secreted by many types of immune cells including Th2, Tregs, Tr1 (IL-10-producing
FoxP3-CD4+ T cells), Th3 (TGFβ and IL-10-producing CD4+ T cells induced in oral tolerance),
NKT cells, B cells, macrophages, and DCs [5]. IL-10 binds to its heterodimeric receptor,
composed of unique for IL-10 subunit (IL-10Rα) and shared with IL-22 subunit (IL-10Rβ).
Although not completely sufficient, STAT3 is required for the inhibitory functions of IL-10.
Importantly, STAT3 induces the expression of transcription factors that regulate various
cytokine signaling pathways including IL-6. IL-10 down-regulates IL-12 production and
expression of co-stimulatory molecules in macrophages and DCs, thereby reducing the Th1
response generation [5].
IL-10 is a key regulator of the immune system by limiting the inflammatory responses that
could otherwise cause tissue damage. IL-10 is essential for homeostasis of the immune system,
especially in the gastrointestinal tract where the tolerance is most needed. Evidence for that is
the highly-susceptible-to-colitis IL-10-deficient mice which develop aberrant immune re-
sponses to commensal bacteria. This colitis is more severe when combined with a deficiency
in TGFβ signaling [5].
Small intestine and colonic lamina propria showed the highest frequency of IL-10-expressing
cells. Recent findings show that macrophages in the lamina propria preferentially induce IL-10-
producing cells while DCs promote the generation of Th17 cells. On one hand, blocking IL-10
during infection can result in more severe pathology or even fatality of the host, but on the
other hand, high production of IL-10 is associated with sustained chronic infections and its
blockade promotes pathogen clearance. Thus, once again, the milieu of the intestines favors
the generation of IL-10-producing T cells leading to tolerance against commensal bacteria,
whereas the expression of IL-10 in peripheral tissues under infectious conditions leads to
suppression of the immune response [5]. In line with this, when IL-10 was previously found
to be abundantly expressed by macrophages in areas of dense inflammatory infiltrate, it had
been directly related to the attenuation of the mucosal inflammation [14]. Knowing nowadays
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about the dual role of IL-10, it is not unexpected that IL-10 is presented at a higher level in the
inflamed mucosa of IBD patients [13]. These findings were confirmed by us as well [24].
Some IL-10 gene polymorphisms have been associated with susceptibility to IBD (i.e. IL-10—
1082) and more significantly with UC alone. Whether the polymorphisms are directly involved
in regulating cytokine production, and consequently disease pathophysiology of IBD, or serve
merely as markers that are in linkage disequilibrium with susceptibility genes, is still unclear
[15].
The involvement of IL-10 in the regulation of the pathogenic function of Th17 cells has been
definitively demonstrated in experiments where non-pathogenic Th17 subtype expressing
IL-10 is generated by IL-6 and TGFβ1, even though in the absence of IL-23. These cells also
prevent the induction of the disease in an IL-10-dependent manner [35]. Even though IL-10
effectively treats colitis in mouse models and suppresses inflammatory cytokine production
in vitro in intestinal cells of patients with IBD, clinical trials using recombinant IL-10 to treat
IBD in humans have been largely disappointing, irrespective of the acceptable side-effect
profile of the therapy [36].
2.7. Role of innate lymphoid cells in gut inflammation
Innate lymphoid cells (ILCs) are recently described cells that have been involved in both
maintenance and loss of gut homeostasis. ILCs are phenotypically and functionally distinct
subsets of cells that inhabit the intestinal mucosa. However, they produce cytokines associated
with effector T-cell responses early in inflammatory lesions of patients with IBD [37]. The novel
family of cells comprises three subsets: ILC1, ILC2, and ILC3 [38]. ILC1 express the transcrip-
tion factor T-bet resembling Th1 cells with production of IFN-γ and TNF; thus, they contribute
to host resistance to intestinal pathogens. ILC2 produce Th2 cytokines, such as IL-5 and IL-13,
and they are dependent on the transcription factor GATA-3. ILC3 which express the transcrip-
tion factor RORγt produce IL-17A and IL-22 mirroring Th17 cells [37]. ILC3 is involved in gut
homeostasis by secreting IL-22 and promoting IL-10 and antimicrobial peptide production.
Epithelial stress-induced ligands and inflammatory conditions may switch ILC3 to ILC1
secreting TNF and IFN-γ under the influence of IL-12. The pro-inflammatory cytokines of ILC1
and ILC3 lead mainly to epithelial apoptosis and neutrophil recruitment. ILC2 are able to
contribute to IBD complications by producing the fibrogenic cytokine IL-13 [37].
Since ILCs might be substantial drivers of mucosal inflammation, targeting ILC subsets may
be a new exciting treatment option for IBD patients.
3. Conclusion
From a clinical perspective, IBD is a chronic persistent disease characterized by repeated
relapses and remissions. One explanation could be that memory Th cells created during the
disease development persist in the body, including during remission, in a manner that is
dependent on the various cytokine presentations. Effector cytokines in the mucosa may induce
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inflammation at the time of the initial episode and during relapses. However, the ambiguity
and contradictory actions of given cytokines confound the understanding of their interactions
in dynamics of the immune response, and that leads to lack of synonymous conclusions about
them. There is still strong need for further investigation, particularly in the gut mucosa, to fully
comprehend their roles in the complex dynamic network of the immune mediators.
Th17 cells have been shown to play a central role in murine and human IBD. Inhibition of the
Th17 pathway may be a promising treatment for IBD, with respect to the role of other subsets
of Th1 and Th2 cells. The data in the literature and our own experience make us believe that
in order to achieve immune homeostasis in the gut, pro-inflammatory and anti-inflammatory
responses that define the mucosal cell immunophenotype, should achieve balance. Thus,
following the clinical periods of remissions and relapses, it is important to observe their
immunological equivalents in the gut and possibly in whole blood, namely regulatory and
pro-inflammatory cytokines secreted by different types of immunocompetent cells.
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